Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma
Open Access
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 50 (1), 37-46
- https://doi.org/10.1080/10428190802563355
Abstract
Tumor-specific variable regions of the clonal immunoglobulin (idiotype, Id) expressed by B cell non-Hodgkin lymphoma (NHL) can be targeted by active immunotherapy. We conducted a phase I/II trial to determine the safety and immunogenicity of a patient-specific, recombinant, mammalian cell-derived Id protein conjugated to keyhole limpet hemocyanin (Id-KLH; MyVax® personalised immunotherapy) in 22 patients with follicular NHL in first remission after chemotherapy. Subjects received five subcutaneous immunisations with MyVax® plus locally administered granulocyte-macrophage colony-stimulating factor (GM-CSF). Among 21 evaluable patients, 62% mounted Id-specific immune responses. Evoked anti-Id antibodies recognised both recombinant Id and native Id, and could specifically stain autologous tumor cells. At median follow-up of more than 6 years, median progression-free survival is 38 months. Immunisation of follicular lymphoma patients with MyVax® Id-KLH is safe and patients often mount tumor-specific immune responses. These results form the basis of a pivotal phase 3 trial of MyVax® in follicular NHL.This publication has 45 references indexed in Scilit:
- Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular LymphomaJNCI Journal of the National Cancer Institute, 2006
- Phase I Trial of a Novel Intradermal Idiotype Vaccine in Patients with Advanced B-Cell Lymphoma: Specific Immune Responses Despite Profound ImmunosuppressionCancer Research, 2006
- Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma AntigenClinical Cancer Research, 2004
- Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor GenotypeJournal of Clinical Oncology, 2004
- Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)Clinical Immunology, 2001
- Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes.The Journal of Experimental Medicine, 1994
- Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor: II. Characterization of anti-idiotypic CTL lines and clonesCellular Immunology, 1992
- Shared Idiotypes Expressed by Human B-Cell LymphomasThe New England Journal of Medicine, 1989
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyThe New England Journal of Medicine, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958